The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.